Statins provide effective secondary prevention of cardiovascular events after acute coronary syndrome (ACS). Current guidelines recommend that statins be initiated in ACS patients before hospital discharge. In this retrospective study, we investigated the influence of early compared with late in-hospital initiation of statin therapy on the clinical outcomes of ACS patients.
ing from coronary plaque rupture with subsequent thrombosis formation of the underlying coronary atherosclerosis and causes acute myocardial ischemia. Patients suffering from ACS have a significantly increased incidence of recurrent cardiac events during follow-up. 5) In addition to the potent effect of lowering lowdensity lipoprotein (LDL), statins improve endothelial function, 6, 7) decrease inflammation, 8, 9) and reduce thrombus formation. 10, 11) Clinical data from recent observational and randomized studies suggest that statins with pleiotropic effects provide clinical benefit in ACS and favor their administration in ACS patients. [12] [13] [14] [15] [16] [17] [18] [19] Stenestrand and Wallentin 12) showed that the 1-year mortality was lower in ACS patients discharged taking statins than in those not taking statins. In the retrospective analysis of the combined GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) IIb and PUR-SUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy) trials, ACS patients receiving statin therapy before hospital discharge had lower mortality rates than did the patients who did not receive statin therapy. 13) In the OPUS-TIMI 16 (Orbofiban in Patients with Unstable Coronary Syndromes) trial, similar results, a lower mortality rate after discharge, were also observed in patients treated with statins during hospitalization. 14) Prospective, randomized trials in ACS patients also suggest that early statin therapy provides a better clinical outcome. The Lipid-Coronary Artery Disease (L-CAD) study randomized 126 patients with ACS to early treatment with pravastatin or to usual care. At 24 months, the patients who received early statin treatment had a lower incidence of clinical events than did the usual-care group. 15) In the MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) study, statin or matching placebo therapy was initiated in ACS patients within 24 to 96 hours after admission. The statin users had a statistically significant 16% lower rate of death and nonfatal major cardiac events than did the nonstatin users at 4 months of follow-up. 16) Colivicchi, et al showed that initiation of atorvastatin therapy before hospital discharge significantly reduced the incidence of ischemic events over a 12-month follow-up after ACS.
17) The A to Z trial showed a favorable trend toward a reduction in major cardiac events during follow-up in ACS patients receiving an early intensive statin therapy. 18) In the PROVE IT (Pravastatin or Atorvastatin Evaluation and Infection Therapy) trial, high-dose atorvastatin therapy initiated within 10 days of admission for ACS provided greater protection against morbidity and mortality than did the usual dose of statin. 19) Because the results of most of these studies were positive, current guidelines suggest that statin therapy should be initiated after an ACS event in the hospital before discharge. However, several issues regarding statin therapy in ACS patients are still unresolved. First, in previous studies, the timing of statin therapy initiation varied, Vol 48 No 6 ranging from 1 to 12 days after hospital admission. Although several recent studies favor the very early use of a statin (within 1-2 days) after ACS, it remains uncertain how soon the statin should be started after ACS. Second, the lipid-lowering therapy received by the control groups in these previous studies also varied; in most cases, only placebo and not a statin was used. It is unknown whether very early initiation of statin therapy (within 1-2 days) after an ACS is more clinically beneficial than is the late initiation of statin therapy, ie, just before hospital discharge. Therefore, the aim of this retrospective observational study was to evaluate whether the very early initiation of statin therapy after ACS (≤ 2 days) is associated with a better clinical outcome than is the late initiation (> 2 days after ACS but before hospital discharge) of statin therapy
METHODS

Study population:
We collected data from all patients admitted to our hospital with the diagnosis of their first episode of ACS from 1 January 2000 to 31 December 2004. Medical records were reviewed, and all patients who had an available lipid profile after their ACS diagnosis was made were identified and included in the analysis. We only included patients with no history of statin use and who began statin therapy during their hospital stay. A total of 210 patients (mean age, 62 years; 158 men) formed the basis of this study and were divided into 2 groups: an early statin group (received statin treatment ≤ 2 days after admission; mean initiation date 1.72 ± 0.45 days, [1-2 days]) and a late statin group (received statin treatment > 2 days after admission and before discharge; mean initiation date 4.45 ± 2.10 days, [3-16 days] ). The diagnosis of ACS (unstable angina or acute myocardial infarction) was based on a history of prolonged ischemic chest pain, characteristic electrocardiographic changes, and elevation of cardiac markers. After being admitted to the hospital, all patients received standard medical treatment for ACS according to the American College of Cardiology/American Heart Association guidelines. 20, 21) A lipid profile including total cholesterol, triglycerides, and LDL and high-density lipoprotein (HDL) cholesterol concentrations was established within 3 days after admission. Coronary angiography results were reported by the cardiologists in charge. Coronary artery disease was defined as ≥ 50% diameter narrowing in a major coronary artery or its major branches. The coronary arteries were grouped as the left anterior descending artery or diagonal and septal branch, left circumflex artery or obtuse marginal branch, and right coronary artery or posterior descending, and posterolateral branch when 1-, 2-, or 3-vessel disease was defined. Revascularization procedures were performed on 113 patients, either by percutaneous coronary intervention (n = 95) or by coronary graft bypass surgery (n = 18). On the basis of the electrocardiographic diagnostic criteria, 97 patients had ST-segment elevation myocardial infarction, 101 patients had non-ST-segment elevation myocardial infarction, and 12 patients had unstable angina. The site of infarction was anterior in 68 patients, inferior in 71 patients, and at the other locations in 59 patients. The Killip classification, 22) based on physical findings during admission, was determined in each patient as a prognostic guide. The left ventricular ejection fraction was measured using Teichholz's formula from transthoracic echocardiography, 23) and left ventricular dysfunction was defined as a left ventricular ejection fraction < 40%. A history of stroke, including ischemic and hemorrhagic stroke, was recorded. Abnormal liver function was defined as elevated aspartate aminotransferase (> 40 U/L) and alanine aminotransferase (> 50 U/L) concentrations during the hospital stay. Abnormal renal function was defined as a serum creatinine concentration > 2 mg/dL during the hospital stay. Study endpoints: All patients were followed-up in our outpatient clinics until the first occurrence of a component of the composite endpoint: cardiovascular death, recurrent myocardial infarction, documented angina requiring rehospitalization, revascularization with either percutaneous coronary intervention or coronary artery bypass grafting (if these procedures were performed ≥ 30 days after discharge), and stroke. Myocardial infarction was defined by the presence of symptoms suggestive of ischemia or infarction, with either electrocardiographic evidence (new Q waves in two or more leads) or cardiac-marker evidence of infarction. Unstable angina was defined as ischemic discomfort at rest for ≥ 10 minutes, prompting rehospitalization, plus ischemic electrocardiographic changes. All patients were followed-up after discharge until the first occurrence of a component of the composite endpoints or for ≥ 1 year after discharge. Follow-up data for these patients were obtained by conducting a detailed chart review and by contacting the patients or their families if necessary. The study protocol was approved by the Institutional Committee of our hospital. Statistical analysis: The clinical characteristics of the early and late statin users were compared. The chi-square test or Fisher's exact test was used to evaluate the differences in categorical variables, and the unpaired Student t test was used to test the differences in continuous variables. Univariate and multivariate Cox proportional hazards models were used to examine the correlations between clinical characteristics as well as early statin use and composite endpoints. Univariate analysis was performed on all baseline characteristics. The predictors with P values < 0.15 in the univariate analysis were then entered into a multivariate model by using a forward stepwise selection algorithm with a threshold of 0.05. During the analyses, the early statin treatment was forced into the multivariate models. Time to the occurrence of a composite endpoint at 4 months was presented as Kaplan-Meier curves for the groups stratified by early or late statin use with a Vol 48 No 6 log-rank test. Hazard ratios and their 95% confidence intervals were calculated. All data are expressed as the mean ± SD. A P value < 0.05 was considered statistically significant. The statistical analyses were carried out using SPSS 13.0 (SPSS Inc, Chicago, IL) for Windows.
RESULTS
A total of 210 patients were enrolled in this study. The baseline characteristics of the early (n = 98) and late (n = 112) statin groups are shown in Table I . No significant differences were observed in age (61 ± 13 and 63 ± 13 years; P = 0.301) or sex (77% and 73% men; P = 0.468) between the early and late statin groups, respectively. Values related to clinical presentation, severity of coronary artery disease, left ventricular systolic function, and cardiac risk factors were not significantly different between the groups. At the time of admission, the cholesterol (220 ± 40 versus 222 ± 46 mg/dL, respectively; P = 0.739) and LDL (161 ± 45 versus 174 ± 116 mg/dL, respectively; P = 0.298) levels of the early and late statin groups were not significantly different. The percentages of patients with abnormal liver and renal function were also not significantly different between the 2 groups.
A comparison of adjunctive medication use in the 2 patient groups is provided in Table II . Within 24 hours after admission, the patients in the late statin group were more likely to be given tirofiban (24% compared with 39%; P = 0.022) and calcium antagonists (8% compared with 20%; P = 0.018). However, at the time of hospital discharge, no significant differences in the use of cardiovascular medications were observed between the early and late statin group. During the follow-up period, the percentages of patients meeting the LDL goal of (2) 1 (1) 7 (7) 4 (4) 2 (2) 6 (5) 4 (4) 13 (12) 9 (8) 1 (1) 0.207 0.213 0.238 0.214 0.513 2 (2) 3 (3) 19 (19) 8 (8) 2 (2) 7 (6) 6 (5) 30 (27) 17 (15) 2 (2) < 100 mg/dL (according to the National Cholesterol Education Program Adult Treatment Panel III for patients with coronary artery disease) were also not significantly different (P = 0.704) between the early (24%) and late (26.4%) statin groups.
Follow-up data at 4 months were available for all patients (Table III) . At 4 months, 39 patients (19% of the cohort) had developed ≥ 1 component of the composite endpoint. The results of univariate analyses for the prediction of the composite outcome at 4 months are presented in Table IV . Together with early or late statin use, all variables listed in Table IV that have a P value < 0.15 were entered into a multivariate Cox regression analysis. In multivariate analyses, after adjustment for other clinical factors, a Killip IV classification and abnormal renal function were found to be independent predictors of the composite endpoint (Table V) ; hazard ratios were 4.79 (95% confidence interval:1.92 to 7.98; P = 0.001) and 2.63 (95% confidence interval: 1.29 to 5.37; P = 0.008), respectively. Early statin treatment has no significant influence on the composite endpoint at 4 months after discharge (hazard ratio: 1.11; 95% confidence interval: 0.54 to 2.25; P = 0.78). At 4 months after discharge, event-free survival was 85% in the early statin group and 79% in the late statin group. The event-free curve was evaluated with the Kaplan-Meier method using a log-rank test. No significant influence (log-rank test: P = 0.539) of the early statin treatment was observed on event-free survival at 4 months (Figure) . When we extended the follow-up period to 12 months after discharge, 64 patients (30% of the cohort) had developed ≥1 component of the composite endpoint. In multivariate analyses, after adjustment for other clinical factors, a Killip IV classification, smoking, and abnormal renal function were found to be independent predictors of the composite endpoint; hazard ratios were 3.40 (95% confidence interval: 1.45 to 7.98; P = 0.005), 2.81 (95% confidence interval: 1.51 to 5.24; P = 0.001), and 3.26 (95% confidence interval: 1.76 to 6.05; P < 0.001), respectively. Early statin treatment still had no significant influence on the composite endpoint 12 months after discharge (haz- Figure. Kaplan-Meier curves for event-free survival at 4 months stratified by in-hospital early or late initiation of statin therapy. The event-free rate for composite endpoint was 85% in the early statin group compared with 79% in the late statin group (P = 0.539 by log-rank test).
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ard ratio: 1.53; 95% confidence interval: 0.83 to 2.81; P = 0.17).
DISCUSSION
The results of our study suggest that the early statin users (within 48 hours after hospital admission) had a risk of adverse cardiovascular events and mortality that was similar to that of the late statin users (before discharge) at 4 and 12 months after the primary ACS event. Thus, the policy of initiating statin therapy in ACS patients within 2 days of hospital admission does not confer better clinical benefit than does initiating statin therapy > 2 days after hospital admission (before discharge). In recent years, the utility of statins for the treatment of ACS has emerged because of their pleiotropic effects and positive results in clinical trials. Currently, available data support the routine initiation of statin therapy in ACS patients before hospital discharge to reduce the risk of recurrent coronary events in the months following the primary event. Although statin therapy is beneficial in ACS patients, it still remains uncertain how early statins should be started after an ACS event. Several recent studies emphasized the benefit of the very early use of a statin (within 24 -48 hours of admission) in patients who experienced acute myocardial infarction. In the National Registry of Myocardial Infarction 4 Study, statin use initiated within 24 hours after hospital admission was associated with a lower risk of in-hospital mortality than was no statin use. 24) Early statin use was also associated with a lower incidence of cardiogenic shock, arrhythmias, cardiac arrest, and rupture, but not of recurrent myocardial infarction. In a report from the first Euro Heart Survey on ACS, a significantly lower 7-day mortality rate was observed in ACS patients who received early statin therapy (within 24 hours) after hospital admission for ST-segment elevation ACS than in nonstatin users. 25) In the PACT (Pravastatin in Acute Coronary Treatment) trial, pravastatin was administered within 24 hours of the onset of symptoms in ACS patients and showed a favorable, but not significant, trend in improving clinical outcome at 30 days compared with placebo. 26) In the previously mentioned studies, the matched cohort of patients in the control group usually received placebo only and did not receive any statins.
The results of the present study indicate that very early initiation of statin therapy in ACS patients, ie, within 48 hours after hospital admission, did not result in better event-free survival than did initiation of statin therapy > 2 days after hospital admission. The potential mechanisms for the benefit of early statin use in ACS patients are a decrease in the extent of myocardial necrosis, an attenuation of ventricular remodeling, a reduction in inflammatory cell accumulation in the ischemic myocardium, an increase in nitric oxide production, and the alleviation of oxidative stress and monocyte adhesion. 6, 27, 28) Because all of these pathophysiologic events can persist for several days to weeks after an ACS event, statin therapy initiated during admission will be early enough to modify these processes and provide clinical benefits. Currently, statins are underutilized after an acute coronary event. Initiation of statin therapy while the patient is still in the hospital will enhance the persistence of statin use in the subsequent year. 29) In our study, only about 25% of the ACS patients met the LDL goal of < 100 mg/dL during the follow-up period. A previous large-scale survey also showed that only 18% of patients with coronary artery disease achieved the LDL target after statin treatment. 30) Therefore, it is more important to encourage the initiation of statin therapy before hospital discharge and to aggressively attempt to lower LDL concentrations to the target level than to emphasize the very early use of statins.
Our study had several limitations. The data represent results from a singlecenter retrospective study and should be interpreted within that context. Because no single statin was mandated, our patients were treated initially with a variety of statins, including pravastatin (39%), simvastatin (30%), atorvastatin (22%), and fluvastatin (9%). The effect of a specific statin on clinical outcome was not a focus of this study and is thus unknown. The differences in the other cardiovascular medications used between the groups may have influenced the results of this study; however, the possible drug effect was justified during the multivariate analyses. Our data are also limited by the small numbers of patients and events studied. Additional adequately powered prospective randomized clinical trials are needed to confirm our findings. In conclusion, our data indicate that no significant differences in the clinical outcomes of ACS patients were observed as a result of early or late in-hospital initiation of statin therapy. Therefore, in the management of ACS, it is important to emphasize the initiation of statin therapy during hospital admission. The immediate initiation of statin therapy, ie, within 48 hours after an ACS event, does not confer a better clinical outcome than does late statin use before discharge.
